Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F and Szlosarek PW
Pharmacological Reports, Springer Nature vol. 75 (3), 753-753.  
17-05-2023

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F and Szlosarek PW
Pharmacological Reports, Springer Nature vol. 75 (3), 570-584.  
03-04-2023

Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy
Gonzalez-Pastor R, Hernandez Y, Gimeno M, de Martino A, Man YKS, Hallden G, Quintanilla M, de la Fuente JM and Martin-Duque P
Acta Biomaterialia, Elsevier vol. 134, 593-604.  
26-07-2021

Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer
Stella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J and Halldén G
Scientific Reports, Springer Nature vol. 9 (1) 
06-09-2019

ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY
Hallden G, Wang Y, Wong H-H and Lemoine NR
In Advanced Textbook On Gene Transfer, Gene Therapy and Genetic Pharmacology, World Scientific Publishing 323-345.  
17-07-2019

Advances in oncolytic adenovirus therapy for pancreatic cancer
Nattress CB and Halldén G
Cancer Letters, Elsevier vol. 434, 56-69.  
05-07-2018

Designer Oncolytic Adenovirus: Coming of Age
Baker AT, Aguirre-Hernández C, Halldén G and Parker AL
Cancers, Mdpi vol. 10 (6) 
14-06-2018

The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells
Man YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL and Halldén G
Molecular Cancer Therapeutics, American Association For Cancer Research (Aacr) vol. 17 (2), 575-587.  
01-02-2018

Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy
Aguirre-Hernández C, Maya-Pineda H, Millán JS, Man YKS, Lu Y-J and Halldén G
Oncogenesis, Springer Nature vol. 7 (1) 
24-01-2018

Targeting pancreatic and prostate cancer with E1B19K-deleted oncolytic adenoviruses
Hallden G
 
01-08-2017

Oncolytic adenovirus-mediated therapy for prostate cancer
Sweeney K and Halldén G
Oncolytic Virotherapy, Taylor & Francis vol. 5, 45-57.  
01-07-2016

The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11
Pantelidou C, Cherubini G, Lemoine NR and Halldén G
Oncotarget, Impact Journals vol. 7 (13), 15703-15724.  
10-02-2016

Oncolytic adenoviral mutants deleted in the anti-apoptotic E1B19K gene sensitize pancreatic cancer cells to drug-induced DNA damage
Pantelidou C, Man YKS, Coughlan L, Marshall J, Kocher H and Hallden G
International Journal of Molecular Medicine vol. 38, S58-S58.  
01-01-2016

The adenoviral AdΔΔ mutant enhances mitoxantrone-induced apoptosis and attenuates drug-induced autophagy in prostate cancer cells.
Aguirre-Hernandez C, Millan JS and Hallden G
 
01-01-2016

18: ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY
Hallden G, Wang Y, Wong H-H and Lemoine NR
In Advanced Textbook On Gene Transfer, Gene Therapy and Genetic Pharmacology, World Scientific Publishing 307-329.  
14-01-2014

Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells.
Passaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Halldèn G, Gillespie D and Portella G
Endocr Relat Cancer vol. 20 (5), 633-647.  
01-10-2013

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.
Halldén G and Portella G
Expert Opin Ther Targets vol. 16 (10), 945-958.  
01-10-2012

Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models.
Adam V, Ekblad M, Sweeney K, Müller H, Busch KH, Johnsen CT, Kang NR, Lemoine NR and Halldén G
Hum Gene Ther vol. 23 (9), 1003-1015.  
01-09-2012

Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo.
Botta G, Passaro C, Libertini S, Abagnale A, Barbato S, Maione AS, Hallden G, Beguinot F, Formisano P and Portella G
Hum Gene Ther vol. 23 (6), 623-634.  
01-06-2012

Abstract 2712: A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells
Sweeney KG, Cheong SC, Lemoine NR and Hallden G
Cancer Research, American Association For Cancer Research (Aacr) vol. 72 (8_Supplement), 2712-2712.  
15-04-2012

Abstract 2713: Adenovirus E1A binding to p300 is essential for synergistic cell killing in combination with chemotherapeutic drugs in prostate cancer cells
Maya-Pineda HR, Miranda-Rota E, Lemoine NR and Halldén G
Cancer Research, American Association For Cancer Research (Aacr) vol. 72 (8_Supplement), 2713-2713.  
15-04-2012

Adenoviral gene expression and replication in human tumor explant models.
Halldén G
Methods Mol Biol vol. 797, 65-78.  
01-01-2012

Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.
Miranda E, Maya Pineda H, Öberg D, Cherubini G, Garate Z, Lemoine NR and Halldén G
Plos One vol. 7 (10) 
01-01-2012

The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models.
Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Müller H, Lemoine NR and Halldén G
Gene Ther vol. 18 (12), 1157-1165.  
01-12-2011

An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR and Halldén G
Cancer Gene Ther vol. 18 (10), 734-743.  
01-10-2011

Adenovirus sensitizes pancreatic cancer cells to DNA-damaging chemotherapeutics through mitotic catastrophe induction and this is further enhanced by the deletion of the anti-apoptotic E1B19K gene
Pantelidou C, Cherubini G, Lemoine NR and Hallden G
Human Gene Therapy vol. 22 (10), A119-A120.  
01-01-2011

A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells
Sweeney K, Cheong SC, Lemoine N and Hallden G
Human Gene Therapy vol. 22 (10), A122-A122.  
01-01-2011

Adenovirus CIA binding to p300 is essential for synergistic cell killing in combination with chemotherapeutics in prostate cancer cells
Maya-Pineda H, Miranda E, Lemoine N and Hallden G
Human Gene Therapy vol. 22 (10), A104-A104.  
01-01-2011

Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer.
Ingemarsdotter CK, Baird SK, Connell CM, Öberg D, Halldén G and McNeish IA
Oncogene vol. 29 (45), 6051-6063.  
11-11-2010

Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR and Halldén G
Hum Gene Ther vol. 21 (10), 1311-1325.  
01-10-2010

Adenovirus-based therapy for prostate cancer.
Ekblad M and Halldén G
Curr Opin Mol Ther vol. 12 (4), 421-431.  
01-08-2010

Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.
Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR and Halldén G
Clin Cancer Res vol. 16 (2), 541-553.  
15-01-2010

P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion.
Lee M, Choi S, Halldén G, Yo SJ, Schichnes D and Aponte GW
Am J Physiol Gastrointest Liver Physiol vol. 297 (4), G641-G654.  
01-10-2009

Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics
Hallden G
J Buon vol. 14, S61-S67.  
01-09-2009

Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR and Halldén G
Clin Cancer Res vol. 15 (5), 1730-1740.  
01-03-2009

Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus d/922-947
Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R, Hallden G and Portella G
Clin Cancer Res vol. 14 (20), 6505-6514.  
15-10-2008

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V, Shen Y and Seymour LW
Hum Gene Ther vol. 19 (9), 873-886.  
01-09-2008

Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic Adenovirus.
Seymour LW, Bazan-Peregrino M, Carlisle R, Hernandez-Alcoceba R, Iggo R, Homicsko K, Hallden G, Mautner V, Shen J and Fisher K
Hum Gene Ther 
27-06-2008

E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.
Cheong SC, Wang Y, Meng J-H, Hill R, Sweeney K, Kirn D, Lemoine NR and Halldén G
Cancer Gene Ther vol. 15 (1), 40-50.  
01-01-2008

Lysis of dysplastic but not normal oral keratinocytes and tissue-engineered epithelia with conditionally replicating adenoviruses
Gaballah K, Hills A, Curiel D, Hallden G, Harrison P and Partridge M
Cancer Res vol. 67 (15), 7284-7294.  
01-08-2007

GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells
Choi S, Lee M, Shiu AL, Yo SJ, Hallden G and Aponte GW
Am J Physiol-Gastr L vol. 292 (5), G1366-G1375.  
01-05-2007

Oncolytic virotherapy for nasopharyngeal cancer
Bapat U, Wang Y, Alusi G, Chisholm E, Francis J, Hallden G and Lemoine N
Clinical Otolaryngology, Wiley vol. 31 (6), 582-583.  
01-12-2006

Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu T-C, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR and Kirn D
Gene Ther vol. 12 (17), 1333-1346.  
01-09-2005

Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors.
Wang Y, Xue S-A, Hallden G, Francis J, Yuan M, Griffin BE and Lemoine NR
Cancer Res vol. 65 (4), 1523-1531.  
15-02-2005

Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activity.
Lee M, Hadi M, Halldén G and Aponte GW
J Biol Chem vol. 280 (1), 125-136.  
07-01-2005

A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.
Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D and Halldén G
Clin Cancer Res vol. 11 (1), 351-360.  
01-01-2005

Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite.
Wang Y, Faux SP, Hallden G, Kirn DH, Houghton CE, Lemoine NR and Patrick G
Int J Oncol vol. 25 (1), 173-178.  
01-07-2004

An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.
Liu T-C, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N and Kirn D
Mol Ther vol. 9 (6), 786-803.  
01-06-2004

Replication-selective oncolytic adenoviruses.
Halldén G, Thorne SH, Yang J and Kirn DH
Methods Mol Med vol. 90, 71-90.  
01-01-2004

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.
Wang Y, Hallden G, Hill R, Anand A, Liu T-C, Francis J, Brooks G, Lemoine N and Kirn D
Nat Biotechnol vol. 21 (11), 1328-1335.  
01-11-2003

Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.
Halldén G, Hill R, Wang Y, Anand A, Liu T-C, Lemoine NR, Francis J, Hawkins L and Kirn D
Mol Ther vol. 8 (3), 412-424.  
01-09-2003

The emerging fields of suicide gene therapy and virotherapy.
Kirn D, Niculescu-Duvaz I, Hallden G and Springer CJ
Trends Mol Med vol. 8 (4 Suppl), S68-S73.  
01-01-2002

Expression of intestinal fatty acid binding protein in intestinal epithelial cell lines, hBRIE 380 cells
Hallden G, Holehouse EL, Dong X and Aponte GW
American Journal of Physiology, American Physiological Society vol. 267 (4), g730-g743.  
01-10-1994

Trophic effect of amniotic fluid on cultured fetal gastric mucosal cells
Mulvihill SJ, Hallden G and Debas HT
Journal of Surgical Research, Elsevier vol. 46 (4), 327-329.  
01-04-1989

Purification of the pancreatic cholecystokinin receptor
Szecowka J, Hallden G, Goldfine ID and Williams JA
Peptides, Elsevier vol. 24 (3), 215-224.  
01-03-1989